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SUMMARY – Fabry disease (Anderson-Fabry disease) is one of the most common lysosomal 
storage diseases (after Gaucher disease) caused by deficient activity of the α-galactosidase A (α-Gal 
A) enzyme, which leads to progressive accumulation of globotriaosylceramide in various cells, pre-
dominantly in endothelium and vascular smooth muscles, with multisystem clinical manifestations. 
Estimates of the incidence range from one per 40,000 to 60,000 in males, and 1:117,000 in the 
general population. Pain is usually the first symptom and is present in 60%-80% of affected chil-
dren, as well as gastrointestinal disturbances, ophthalmologic abnormalities and hearing loss. Renal 
failure, hypertrophic cardiomyopathy, or stroke as the presenting symptom may also be found even 
as isolated symptoms of the disease. Life expectancy is reduced by approximately 20 years in males 
and 10-15 years in females, therefore enzyme replacement therapy should be introduced in patients 
of any age and either sex, who meet treatment criteria for Anderson-Fabry disease.
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Pathophysiology
Fabry disease (Anderson-Fabry disease, AFD) is 
one of the most common lysosomal storage diseases 
(after Gaucher disease). In 1897, William Anderson 
was the first to describe clinical manifestations of Fab-
ry disease as multiple telangiectasias in a 39-year-old 
patient, and in 1898 Johannes Fabry described “an-
giokeratoma corporis diffusum” and proteinuria in a 
13-year-old boy. Fabry disease is an X-linked recessive 
lysosomal storage disorder caused by deficient activity 
of the α-galactosidase A (α-Gal A) enzyme, which 
leads to progressive accumulation of globotriaosylcer-
amide in various cells, predominantly in endothelium 




incapacity of glycosphingolipid catabolism

accumulation of globotriaosylceramide 
(Gb3) in endothelium and visceral organs

multisystem organ failure
Fig. 1. Genetic and molecular basis of Fabry 
disease.
and vascular smooth muscles, with multisystem clini-
cal manifestations, including the nervous system (Fig. 
1). The gene for α-galactosidase A is located on Xq22, 
and more than 585 mutations have been identified. 
Most of them are missense mutations, while other 
can clinically present as a monosymptomatic disease 
or oligosymptomatic diseae (classical clinical picture). 
Due to X-linked recessive pattern of inheritance, 
Fabry disease predominantly affects males, but female 
carriers of the defective gene are also often affected 
(Figs. 2-4)1,2. 
According to Lyon hypothesis and consecutive mo-














Fig. 3. Male X-linked recessive trait segregation.
Fig. 4. Female and male X-linked recessive trait segrega-
tion.
heterogeneity of symptoms is even more pronounced 
(Fig. 5). The symptoms also tend to start later in life 
than in male patients, have slower progression and 
milder clinical manifestations (Table 1). 
Estimates of the incidence range from one per 
40,000 to 60,000 males; in the general population, it 
is estimated to be 1/117,000 in Australia3, 1/476,000 
in The Netherlands4, and as high as 1/15,000 in Nova 
Scotia5. 
Clinical Signs and Symptoms
Clinical signs and symptoms vary between males 
and females in number, severity and time of appear-
ance, as described before. The symptoms usually ap-
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pear during childhood or adolescence6, and by middle 
age, life-threatening complications often develop in 
untreated patients. In the classic Fabry disease, they 
include renal, cardiac and cerebrovascular manifes-
tations that lead to early death. These patients have 
either no or very small amounts of detectable enzyme 
activity, while milder variants have decreased enzyme 
activity. Patients present clinically with chronic neuro-
pathic pain, gastrointestinal disturbances, angiokera-
toma, progressive renal impairment, cardiomyopathy, 
and stroke. Recognition of Fabry disease is still diffi-
cult because of the heterogeneous presentation of the 
disorder. Due to the heterogeneity of symptoms, the 
diagnosis is often missed7; the results from Fabry Out-
come Survey have shown that the mean time between 
the onset of symptoms and diagnosis was 12.4 years 
in females and 12.2 in males8. The so called ‘cardiac 
variant’9,10, ‘renal variant’11 or ‘stroke variant’12 may be 
one of the first and only symptoms of Fabry disease. 
Clinically, they present with late onset hypertrophic 
cardiomyopathy, isolated stroke or isolated end-stage 
renal disease (ESRD) as their initial manifestation. 
Symptoms in childhood and adolescence may vary, 
usually they start between the age of 3 and 10 years, 
often a few years later in girls than in boys12,13. In 60%-
80% of affected children, pain is the first symptom. 
They may experience acute, unexplained episodes of 
burning pain in the extremities, often accompanied 
or triggered by fever (episodic or Fabry crisis). Pain 
diminishes the quality of life, and may even lead to 
anxiety or depression. Chronic pain or discomfort in 
the extremities (acroparesthesia) is another form of 
painful sensation described. These symptoms are due 
to a dysfunctional condition of small nerve fibers14. 
Unexplained gastrointestinal disturbances (nausea, 
vomiting, diarrhea, abdominal discomfort and pain, 
loss of weight) are very common. The most visible ear-
ly clinical sign is angiokeratoma, small raised, dark-
red spots, which are typically found on the buttocks, 
groin, umbilicus and upper thighs. Ophthalmologic 
abnormalities, especially cornea verticillata and reti-
nal vessel tortuosity, hearing impairment or dyshidro-
sis (hypohidrosis or anhidrosis) can be found. Inabili-
ty to sweat leads to heat, cold, and exercise intolerance 
(Table 1). Early signs of cardiac and renal abnormali-
ties may be present during adolescence (proteinuria, 
microalbuminuria, impaired concentration ability, 
impaired heart rate variability, arrhythmias, ECG 
abnormalities, mild valvular insufficiency)15.
Adults often present with worsening of childhood 
symptoms. Isolated end-stage renal failure, hyper-
trophic cardiomyopathy, or stroke as the presenting 
symptom may also be found. Hearing loss is com-
mon, often with rapid onset. More extensive angiok-
Table 1. Onset of Fabry disease symptoms due to age in male patients;in female patients later onset and wide range of 
symptoms in clinical picture
Childhood Adolescence Adulthood
Acroparesthesias Acroparesthesias Acroparesthesias
Pain in limbs Pain in limbs Pain in limbs
Lenticular and corneal changes Lenticular and corneal changes Lenticular and corneal changes
Fever Fever Fever
Heat and cold intolerance Heat and cold intolerance Heat and cold intolerance
Psychosocial changes Psychosocial changes Psychosocial changes
Proteinuria Proteinuria






Hearing loss and tinnitus
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Table 2. Differential diagnosis of Fabry disease according to leading symptoms
Angiokeratoma
Petechiae of meningococcal meningitis (during Anderson-Fabry 
disease crisis)
Hereditary hemorrhagic telangiectasias
Fordyce disease, Schindler disease, fucocidosis
and sialidosis (lysosomal storage diseases)
Systemic lupus erythematosus
Pain






Multiple sclerosis and other demyelinating diseases
Stroke (caused by conventional risk factors, vasculitis, thrombo-
philia)
Different causes of polyneuropathy 
Renal impairment
Before biopsy – more common causes of early onset end stage renal 
failure, e.g., glomerulonephritis, pyelonephritis, exposure to silica 
dust
Cardiac disease









(also called lyonization) is a process by which 
one of the two copies of the X chromosome 
present in female mammals is inactivated 
with consecutive mosaicism of the cells. 
X-inactivation prevents them from having 
twice as many X chromosome gene products 
as males – dosage compensation. The choice 
of which X chromosome will be inactivated 
is random, but once an X chromosome 
is inactivated it will remain inactive 
throughout the lifetime of the cell and its 
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eratomas may be present or can cover only the genital 
area. Nephropathy is one of the major complications 
of Fabry disease and an important cause of death. 
Age at onset of end-stage renal failure is usually in 
the 30s and is not seen in childhood. Abnormalities 
include proteinuria, hematuria, nephrotic syndrome 
and chronic renal failure requiring dialysis and/or 
renal transplantation16. Common cardiac defects in-
clude left and right ventricular hypertrophy, enlarged 
left atrium, heart valve abnormalities, atrial arrhyth-
mia and conduction disturbance, angina, shortness 
of breath, fatigue, and syncope. Cardiac involvement 
may be the only symptom in some hemizygous males10 
and up to 4% of males with hypertrophic cardiomyo-
pathy may have a ‘cardiac’ variant of AFD10. Nervous 
system involvement includes transient ischemic at-
tack (TIA) or stroke17. It is estimated that 1%-2% of 
stroke patients aged 18 to 55 years could have Fabry 
disease18. The mean age recorded for cerebrovascular 
events is around 5 years earlier in men than in wom-
en19,20. Ischemic stroke is considerably more common 
than hemorrhagic stroke19,20, and most are small ves-
sel infarcts. Recent studies19 have shown that nearly 
half of Fabry patiens (45.9%) experienced their first 
stroke before being diagnosed. In fact, the median 
time from stroke to diagnosis was 4.8 years. The prev-
alence of Fabry disease in young patients with crypto-
genic stroke has been reported to be as high as 4.9% 
in men and 2.4% in women18. Other studies suggest 
that α-GAL A deficiency may play a role in up to 
1% of young patients presenting with cerebrovascular 
disease21. Vertebrobasilar dolichoectasia has also been 
reported in Fabry patients17,22. Hyperintensity in the 
pulvinar on T1 weighted images is a common find-
Fig. 6. In most female patients, DNA sequencing as the first step in Fabry diagnosis establishment is obliga-
tory, while in male patients it should be done to confirm the number and type of the GLA gene mutation.
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ing in Fabry disease, likely reflecting the presence of 
calcification. Recent findings suggest that the pulvi-
nar sign is a highly specific sign, distinctively charac-
teristic of Fabry disease21,22. Disturbed concentration, 
dizziness, dementia, headaches, and learning difficul-
ties also occur. The peripheral nervous system may 
also be affected, with disturbances of touch, pain and 
sensitivity to temperature8. Respiratory involvement, 
manifesting as dyspnea with exercise, chronic cough 
and wheezing, is frequent in both genders with Fabry 
disease (Table 1)23,24.
Life expectancy is reduced in both male and female 
patients by approximately 20 years in males and 10-15 
years in females. The Fabry Outcome Survey (FOS) 
data have shown that the principal cause of death in 
males is renal failure, followed by cardiac and cerebro-
vascular incidents. In female patients, the main causes 
of death were cardiac disorders8.
Diagnostic Testing for Fabry Disease
Differential diagnosis of Fabry disease depends 
on the leading signs and symptoms; some of the most 
common states are listed in Table 2. As mentioned 
above, early diagnosis of Fabry disease is difficult. 
Early symptoms in childhood are often subtle and 
nonspecific, and may be easily misinterpreted. The 
median age at diagnosis was about 28 years among 
688 patients in FOS, which was about 16 years after 
the first symptoms had started8. Patients often have to 
visit several medical specialists before a correct diag-
nosis is made. Medical specialists caring for patients 
with renal and cardiac disease or stroke are most likely 
to make a diagnosis, which is highly important since 
enzyme replacement therapy can significantly improve 
the quality of life and medical care. Also, correct di-
agnosis leads to family screening and identification of 
other relatives who are affected or are carriers of the 
disease, enabling genetic counseling and prenatal di-
agnostics (Fig. 6).
After establishment of Fabry disease as a work-
ing diagnosis, it is of great importance to evaluate 
the GLA activity in plasma or peripheral blood leu-
kocytes (plasma and lysosomal GLA), the concentra-
tion of Gb3 in serum and urine, and genetic testing to 
identify the GLA gene mutations. 
Biochemical or molecular prenatal diagnosis of 
Fabry disease can be performed by determination of 
α-gal A activity in direct and/or cultured chorionic 
villi at 10 weeks of gestation, or in cultured amni-
otic cells at about 14 weeks of gestation. Since the 
implementation of enzyme replacement therapy in the 
management of Fabry disease, prenatal diagnosis has 
become ethically and medically questionable.
Diagnostic work up for patient suspect of Fabry 
disease should include:
– General status, quality of life, school or work per-
formance, depression, anxiety, drug use, somatic 
growth 
– Complete physical examination 
– Neurologic examination, questionnaires (Brief 
Pain Inventory)
– Complete laboratory work up (complete blood 
count, erythrocyte sedimentation rate, C-reactive 
protein, serum creatinine, ionogram, BUN; urinary 
protein/creatinine ratio, albumin/creatinine ratio, 
liver function test, glucose levels, thyroid hormones, 
creatine phosphokinase, lactate dehydrogenase)
Table 3. Fabry disease – evaluation of kidney involvement
Organ system Assessment Recommendation
Kidney
Serum electrolytes, creatinine, BUN; 
24-h urine or spot urine for total 
protein/creatinine, albumin/creatine, 
sodium, creatinine
Baseline, every 3 months if CKD stage 1 or 2 and 
>1 g/day of proteinuria or CKD stage 4
Every 6 months if CKD stage 3
Every 12 months if CKD stage 1 or 2 and <1 g/
day of proteinuria
BUN = blood urea nitrogen; CKD = chronic kidney disease
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– Alpha-galactosidase A activity, Gb3 levels in se-
rum and urine, and genotype




– Brain MRI without contrast
– Magnetic resonance angiography
– Evaluation of the head and neck blood vessels by 
means of ultrasound (echo tracking, intima media 
thickness, measurement of vasoreactivity, Color 
Coded Flow imaging and Power Doppler)
– Comorbid stroke risk factors: cholesterol (total, 
LDL, HDL), triglycerides, Lp(a), total plasma 
homocysteine, testing for vasculitis and thrombo-
philia
– Abdominal ultrasound
– Renal biopsy in selected cases
– General ophthalmologic exam 
– Spirometry 
– Endoscopic evaluations of gastrointestinal system 
– Audiometry, tympanometry, otoacoustic emis-
sions Dermatologic examination and skin biopsy 
in selected cases Bone mineral density, 25(OH) 
vitamin D levels
Epidemiology and the Need of Screening
We do not recommend screening in the general 
population. (Ungraded statement)
We recommend obtaining informed consent from 
the patient before screening, using an information 
form drafted in collaboration with a clinical geneti-
cist. (Ungraded statement)
We recommend screening for Fabry disease in 
male chronic kidney disease (CKD) patients below 50 
years of age in whom a reliable renal diagnosis is ab-
sent. (Ungraded statement) (Table 3)
We suggest screening for Fabry disease in females 
with unexplained CKD, irrespective of age, with oth-
er unexplained symptoms potentially associated with 
Fabry disease. (Ungraded statement)
We recommend discussing with the patient the im-
plications of diagnosing a genetic disease and the pos-
sible implications for the at risk relatives. (Level 1C) 
Screening Methods
We recommend using enzyme activity measure-
ment for α-Gal A as a primary tool in males, followed 
by confirmation with mutation analysis when positive. 
(Ungraded statement)
We suggest using mutation analysis as a primary 
tool for screening in females. (Ungraded statement)
Treatment guidelines
Enzyme replacement therapy
Enzyme replacement therapy (ERT) supplies the 
organs with recombinant enzyme and therefore re-
duces THE amount of Gb3 accumulation in tissues 
with consecutive multisystem damage. Treatment of 
Fabry disease with ERT is available since 2001, in 
THE form of two recombinant GLA preparations 
– agalsidase alfa (Replagal, Shire Human Genetic 
Therapies, Cambridge, MA, 0.2 mg/kg per infusion), 
and agalsidase beta (Fabrazyme, Genzyme Corpora-
tion, Cambridge, MA, 1 mg/kg per infusion)25-27.
ERT should be considered in patients of any age 
and either sex, who meet any of the set criteria. 
Diagnostic work up should be performed as well 
as introduction of ERT at clinical hospital centers and 
then continued according to the place of living. 
Renal
It is not recommended to start ERT in patients 
with proteinuria [protein-to-creatinine ratio >1 g/g 
(>0.1=gram/mol) creatinine] or eGFR <60 mL/
min/1.73 m2, except for non-renal indications. (1D)
We recommend that when ERT is deemed indi-
cated, it should be started as part of a well-designed 
clinical trial, either observational or interventional. 
(Ungraded statement)
In a patient on hemodialysis, and when ERT is 
deemed indicated, we recommend administering the 
ERT during a hemodialysis session. (1A)
We recommend kidney transplantation as a valu-
able option in patients who are eligible for this inter-
vention. (Ungraded statement)
After renal transplantation, we do not suggest 
ERT for renal indications, but it can be continued for 
non-renal indications. (Ungraded statement) 
We recommend not considering female carriers for 
living donation, unless in exceptional cases. In these cas-
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es, we recommend a kidney biopsy to evaluate the risk 
for the donor and recipient. (Ungraded statement)29-42.
Cardiac
Any patient with Fabry disease and cardiac disease 
as defined in the criteria for cardiac diagnosis should 
be considered candidate for enzyme replacement, pro-
viding other causes of their cardiac findings have been 
excluded40-42.
Neurological
Transient ischemic attacks documented by a neu-
rologist or early onset central nervous system infarc-
tion, or unexplained, progressive white matter chang-
es identifiable as microvascular changes on magnetic 
resonance imaging25-27.
Gastrointestinal
Severe gastrointestinal symptoms: intractable ab-
dominal pain and diarrhea refractory to other thera-
pies25-27.
Pain
Intractable neuropathic pain refractory to other 
therapies25-27.
Treatment of comorbidities
Specific attention should be paid to cerebrovascu-
lar and cardiovascular risk factors. Patients with Fabry 
disease carry a very high risk of vascular events, so 
the management of other vascular risk factors (hy-
pertension, dyslipidemia, diabetes mellitus, increased 
weight, smoking) should be aggressive25-27.
Symptomatic Treatment 
Pain and painful episodes
Lifestyle modifications (in particular, avoidance of 
stimuli that precipitate Fabry pain, i.e. fatigue, lack 
of sleep) and certain prophylactic medications can be 
useful for symptom management. Diphenylhydantoin 
(Dilantin)15, carbamazcpinc (Tegretol)16 and gabapen-
tin (Neurontin)17 have been found to be effective in 
some patients. Nonsteriodal anti-inflammatory drugs, 
serotonin reuptake inhibitors or tricyclic antidepres-
sants may be used for intermittent pain. Chronic, de-
bilitating pain is managed best by an expert in pain 
management. 
Gastrointestinal symptoms
Pancrelipase or metoclopramide can improve gas-
trointestinal symptoms23.
Psychosocial support
Fabry disease, especially with early onset in child-
hood and adolescence as well as later in life, causes 
many psychosocial problems, therefore it is of great 
importance to include psychiatrist in early treatment 
of Fabry patient.
Follow-up of Fabry disease
Clinical course will determine the frequency of 
tests and clinical evaluation. Detailed baseline and 
follow-up data of all patients with established Fabry 
disease should be transferred to a central registry. 
There should be obligatory baseline and subsequent 
yearly evaluation of asymptomatic Fabry disease pa-
tients, more frequently for symptomatic patients (ev-
ery 3 months), by a multidisciplinary team, including 
kidney function and albuminuria, in all patients with 
established Fabry disease (cardiology, neurology and 
nephrology diagnostic work up)43,44.
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NOMENCLATURE AND DESCRIPTION FOR RATING GUIDELINE 
RECOMMENDATIONES
Within each recommendation, the strength of recommendation is indicated as Level 1 and Level 2, or Not 
Graded and the quality of the supporting evidence is shown as A,B,C or D.
Implications
Grade Patients Clinicians Policy-makers
Level 1
(we recommend)
Most people in your situation 
would want the recommended 
course of action and only a small 
proportion would not
Most patients should 
receive the recommended 
course of action
The recommendation can 
be evaluated as a candidate 




The majority of people in 
your situation would want the 
recommended course of action 
but many would not
Different choices will be 
appropriate for different 
patients. Each patient 
needs help to arrive at 
a management decision 
consistent with her or his 
values and preferences.
The recommendation is 
likely to require substantial 
debate and involvement of 
stakeholders before policy 
can be determined.
*  The additional category „Not graded“was used typically, to provide guidance based on common sense or where the topic does not allow 
adequate application of evidence. The most common examples include recommendation regarding monitoring intervals, counseling, and 
referral to other clinical specialist. The ungraded recommendations are generally written as a simple declarative statement, but are not 
meant to be interpreted as being stronger recommendations than Level 1 or 2 recommendations.
Grade Quality of evidence Meaning
A High We are confident that the true effect lies close to that of the estimate of the effect.
B Moderate The true effect is likely to be close to the estimate to the effect, but there is a possibility that it is substantially different.
C Low The true effect may be substantially different from the estimate to the effect.
D Very low The estimate of the effect is very uncertain, and often will be far from the truth.
404 Acta Clin Croat,  Vol. 52,   No. 3,  2013
Acta Clin Croat 2013; 52:xx-xx Recommendation
References
1. BRADY RO, GAL AE, BRADLEY RM, MARTENS-
SON E, WARSHAW AL, LASTER L. Enzymatic defect 
in Fabry’s disease. Ceramide trihexosidase deficiency. N Engl 
J Med 1967;276:1163-7.
2. PETERS FPJ, VERMEULEN A, KHO TL. Ander-
son-Fabry’s disease: α-galactosidase deficiency. Lancet 
2001;357:138-40.
3. MEIKLE PJ, HOPWOOD JJ, CLAGUE AE, CAREY 
WF. Prevalence of lysosomal storage disorders. JAMA 
1999;281:249-54.
4. POORTHUIS BJ, WEVERS RA, KLEIJER WJ, et al. The 
frequency of lysosomal storage diseases in Netherlands. Hum 
Genet 1999;105:151-6.
5. WEST M, DYACK S, RIDDELL C, LeMOINE K, CAM-
FIELD C, CAMFIELD P. A Nova Scotia kindred with 
Fabry disease. Acta Pediatr 2002;91:439S:116.
6. RIES M, RAMASWAMI U, et al. The early clinical pheno-
type of Fabry disease: a study of 35 European children. Eur J 
Pediatr 2003;162:767-72.
  7. MEHTA A, LEWIS S, LAVERY C. Treatment of lysosom-
al storage disorders. BMJ 2003;327:462-3.
  8. MEHTA A, BECK M, SUNDER-PLASSMANN G. Fabry 
disease: perspectives from 5 years of FOS. Oxford Pharma-
Genesis Ltd., England, 2006.
  9. ELLEDER M, BRADOVA V, SMID F, BUDESIN-
SKY M, HARZER K, KUSTERMANN-KUHN B, et 
al. Cardiocyte storage and hypertrophy as a sole manifesta-
tion of Fabry’s disease. Virch Arch Pathol Anat Histopathol 
1990;417:449-55.
10. NAKAO S, TAKENAKA T, MAEDA M, KODAMA C, 
TANAKA A, TAHARA M, et al. An atypical variant of 
Fabry’s disease in men with left ventricular hypertrophy. N 
Engl J Med 1995;333:288-93.
11. NAKAO S, KODAMA C, TAKENAKA T, TANAKA 
A, YASUMOTO Y, YOSHIDA A, KANZAKI T, EN-
RIqUEZ AL, ENG CM, TANAKA H, TEI C, DESNICK 
RJ. Fabry disease: detection of undiagnosed hemodialysis pa-
tients and identification of a “renal variant” phenotype. Kid-
ney Int 2003;64:801-7.
12. SALVIATI A, BURLINA AP, BORSINI W. Nervous sys-
tem and Fabry disease, from symptoms to diagnosis: damage 
evaluation and follow-up in adult patients, enzyme replace-
ment, and support therapy. Neurol Sci 2010;31:299-306.
13. GERMAIN DP. Fabry disease. Orphanet J Rare Dis 
2010;5:30.
14. TSAKIRIS D, SIMPSON HKL, JONES EHP, et al. Rare 
diseases in renal replacement therapy in the ERA-EDTA 
Registry. Nephrol Dial Transplant 1996;11:4-20.
15. MITSIAS P, LEVINE SR. Cerebrovascular complications 
of Fabry’s disease. Ann Neurol 1996;40:8-17.
16. ROLFS A, BOTTCHER T, ZSCHIESCHE M, MORRIS 
P, WINCHESTER B, BAUER P, et al. Prevalence of Fabry 
disease in patients with cryptogenic stroke: a prospective 
study. Lancet 2005;366:1794-6.
17. SIMS K, POLITEI J, BANIKAZEMI M, LEE P. Stroke in 
Fabry disease frequently occurs before diagnosing and in the 
absence of other clinical events: natural history data from the 
Fabry Registry. Stroke 2009;40:788-94. 
18. SCHIFFMANN R, WARNOCK DG, BANIKAZEMI 
M, BULTAS J, LINTHORST GE, PACKMAN S, et al. 
Fabry disease: progression of nephropathy, and prevalence of 
cardiac and cerebrovascular events before enzyme replace-
ment therapy. Nephrol Dial Transplant 2009;24:2102-11.
19. BROUNS R, THIJS V, EYSKENS F, Van den BROECK 
M, BELACHEW S, Van BROECKHOVEN C, et al. Bel-
gian Fabry Study: Prevalence of Fabry disease in a cohort 
of 1000 young patients with cerebrovascular disease. Stroke 
2010;41:863-8.
20. PASSERO SG, CALCHETTI B, BARTALINI S. Intrac-
ranial bleeding in patients with vertebrobasilar dolichoecta-
sia. Stroke 2005;36:1412-5.
21. MOORE DF, YE F, SCHIFFMANN R, BUTMAN JA. 
Increased signal intensity in the pulvinar on T1-weighted im-
ages: a pathognomonic MR imaging sign of Fabry disease. 
AJNR Am J Neuroradiol 2003;24:1096-101.
22. BURLINA AP, MANARA R, CAILLAUD C, LAISSY 
JP, SEVERINO M, KLEIN I, BURLINA A, LIDOVE O. 
The pulvinar sign: frequency and clinical correlations in Fabry 
disease. J Neurol 2008;255:738-44.
23. ROSENBERG DM, FERRANS VJ, FULMER JD, LINE 
BR, BARRANGER JA, BRADY RO, CRYSTAL RG. 
Chronic airflow obstruction in Fabry’s disease. Am J Med 
1980;68:898-905.
24. BROWN LK, MILLER A, BHUPTANI A, SLOANE 
MF, ZIMMERMAN MI, SCHILERO G, ENG CM, 
DESNICK RJ. Pulmonary involvement in Fabry disease. Am 
J Respir Crit Care Med 1997;155:1004-10.
25. MOTABAR O, SIDRANSKY E, GOLDIN E, ZHENG 
W. Fabry disease – current treatment and new drug develop-
ment. Curr Chem Genomics 2010;4:50-6.
26. DEEGAN PB. Fabry disease, enzyme replacement therapy 
and the significance of antibody responses. J Inherit Metab 
Dis 2012;35:227-43.
27. ELSTEIN D, ALTARESCU G, BECK M. Fabry Disease. 
Dordrecht-Heidelberg-London-New York: Springer, 2010.
28. ENG CM, GERMAIN DP, BANIKAZEMI M, et al. Fab-
ry disease: guidelines for the evaluation and management of 
multi-organ system involvement. Genet Med 2006;8: 539-48.
29. GERMAIN DP, WALDEK S, BANIKAZEMI M, et al. 
Sustained, longterm renal stabilization after 54 months of 
agalsidase beta therapy in patients with Fabry disease. J Am 
Soc Nephrol 2007;18:1547-57.
Acta Clin Croat,  Vol. 52,  No. 3,  2013 405
Acta Clin Croat 2013; 52:xx-xx Recommendation
Sažetak
SMJERNICE ZA DIJAGNOSTICIRANJE, TERAPIJU I PRAĆENJE ANDERSON-FABRYJEVE BOLESTI
V. Bašić Kes, M. Cesarik, I. Zavoreo, S. Soldo-Butković, P. Kes, N. Bašić-Jukić, S. Rački, M. Jakić, D. Delić-Brkljačić, Z. Jukić, 
Z. Trkanjec, V. Šerić, V. Vargek Solter, I. Bielen, S. Bašić i V. Demarin 
Fabryjeva bolest (Anderson-Fabryjeva bolest) je jedna od najčešćih lizosomskih bolesti nakupljanja (nakon Gaucherove 
bolesti) uzrokovana smanjenom aktivnošću enzima α-galaktosidaze A (α -Gal A) uz posljedično nakupljanje globotria-
ozilceramida u različitim stanicama, ponajprije u endotelnim i vaskularnim glatkim mišićnim stanicama uz posljedične 
multisistemske manifestacije. Pojavnost bolesti u muškaraca je 1:40.000-60.000, dok je u općoj populaciji oko 1:117.000. 
Bol je najčešće prvi simptom bolesti u 60%-80% djece, kao i simptomi probavnog sustava, oftalmološki simptomi, gubitak 
sluha. Smanjenje bubrežne funkcije, hipertrofična miokardiopatija ili moždani udar mogu se iskazati kao izolirani simp-
tomi bolesti. Očekivani životni vijek se skraćuje u bolesnika s Fabryjevom bolešću i to u muškaraca za oko 20 godina, a u 
žena za 10-15 godina, stoga je uvođenje enzimske nadomjesne terapije nužno u svih bolesnika bez obzira na dob i spol koji 
zadovoljavaju kriterije za terapiju ove bolesti.
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